Scientific Frontline: Extended "At a Glance" Summary: Keratin 17 (K17) in Pancreatic Cancer
The Core Concept: Keratin 17 (K17) is a protein that has been identified as a primary driver of chemotherapy resistance in highly aggressive forms of cancer, most notably pancreatic ductal adenocarcinoma (PDAC).
Key Distinction/Mechanism: While K17 typically functions as a structural protein during embryonic development, it is re-expressed in cancer cells where it behaves entirely differently. It enters the mitochondria to stabilize dihydroorotate dehydrogenase (DHODH), an enzyme essential for synthesizing pyrimidines (DNA building blocks). This metabolic alteration drastically decreases the tumor's sensitivity to chemotherapy agents like gemcitabine.
Major Frameworks/Components:
- Keratin 17 (K17) Overexpression: The re-emergence of an embryologic protein that influences cell growth, invasion, and survival in adult tumor tissues.
- Mitochondrial Relocation: The atypical mechanism by which K17 enters the mitochondria to alter internal cellular metabolism.
- DHODH Stabilization: The core enzymatic interaction that accelerates pyrimidine biosynthesis.
- Gemcitabine Chemoresistance: The end result of the K17 pathway, which fortifies cancer cells against standard chemical interventions.









.jpg)




